Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient

The survival outcomes of the FLAURA trial support osimertinib as the new standard of care for untreated patients harboring activating mutations in the epidermal growth factor receptor (EGFR). Despite the initial response, disease progression invariably occurs. Although uncommon, BRAF V600E mutation...

Descripción completa

Detalles Bibliográficos
Autores principales: Ribeiro, Maurício Fernando Silva Almeida, Knebel, Franciele Hinterholz, Bettoni, Fabiana, Saddi, Rodrigo, Sacardo, Karina Perez, Canedo, Felipe Sales Nogueira Amorim, Alessi, João Victor Machado, Shimada, Andrea Kazumi, Marin, José Flávio Gomes, Camargo, Anamaria Aranha, Katz, Artur
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7880994/
https://www.ncbi.nlm.nih.gov/pubmed/33580193
http://dx.doi.org/10.1038/s41698-021-00149-4

Ejemplares similares

Ejemplares similares